A Study Investigating the Safety and Efficacy of Bio-Active Silver Hydrosol™ in Providing Immune Support

Inclusion Criteria: 1. Provided voluntary, written, informed consent to participate in the study 2. Females and males between 19 and 65 years of age inclusive 3. Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation) or have been post-menopausal (natural or surgically) for at least 1 year prior to screening Or, 1. Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: 2. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) 3. Double-barrier method 4. Intrauterine devices 5. Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) 6. Vasectomy of partner at least 6 months prior to screening 4. BMI between 18.5 to 29.9 kg/m2 inclusive 5. Individuals participating in an intense aerobic sport (e.g. cycling, running, triathlon, swimming, soccer, Nordic skiing, basketball, hockey, gym etc.) for greater than or equal to 5 hours a week 6. Agrees to provide a verbal history of flu vaccination 7. Healthy as determined by laboratory results, medical history, and physical exam or as determined by the QI 8. Agrees to maintain current diet and exercise programs 9. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits Exclusion Criteria: 1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial 2. Subject has a known allergy to the test material's active or inactive ingredients 3. Verbal confirmation of a diagnosed chronic inflammatory condition 4. Verbal confirmation of the diagnosis of any autoimmune disease or immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis) 5. Chronic consumption of oral anti-inflammatory medications such as cyclosporine for skin conditions such as psoriasis, dermatitis, rosacea 6. Chronic consumption of anti-inflammatory medications or medications known to affect immune function on a daily basis, including medications for allergies and asthma with the exception of Ventolin, within 4 weeks of baseline visit (visit 2) 7. Verbal confirmation of chronic recurring respiratory signs and symptoms due to allergies (including seasonal allergies) or chronic bronchitis 8. Verbal confirmation of active shingles and/or herpes virus infections, within 2 months of baseline 9. Use of medical marijuana including THC-free CBD (any form of consumption) 10. Use of recreational marijuana (any form of consumption) within the past 4 weeks and is unwilling to stop use for the duration of the study 11. Use of immunomodulators (including corticosteroids) such as immunosuppressant or immune-stimulant medications within 4 weeks of baseline 12. Taking antibiotics within 2 weeks of screening 13. Use of immune support supplements unless willing to undergo washout 14. Use of multivitamins unless on a stable regimen for 3 months as assessed by QI 15. Verbal confirmation of Type I or Type II diabetes or clinically important hepatic, cardiac, pulmonary, pancreatic, neurologic, or biliary disorder 16. History or current diagnosis of renal disease with the exception of a history of kidney stones symptom-free for 1 year 17. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable 18. Current or pre-existing thyroid condition. Treatment on a stable dose medication for 6 months will be reviewed on a case-by-case basis by the QI 19. History of or current blood/bleeding disorders with the exception of a history of anemia caused by a deficiency of a mineral or vitamin, and no longer present. 20. Verbal confirmation of the diagnosis of Hepatitis B/C positive 21. Chronic unusual sleep routine (examples: irregular routine with frequent late nights, studying, partying) 22. Use of Prebiotics and Probiotics unless on a stable regimen for 3 months as assessed by QI. 23. Smoking study participants must be willing to abstain from tobacco use in the morning of a clinical visit 24. High alcohol intake (average \>2 standard drinks per day, or ≥15 standard drinks per week for men, or ≥8 standard drinks per week for women) 25. Alcohol or drug abuse in the past year 26. Blood donation during or within 30 days of the last study visit 27. Subjects with unstable medical conditions as assessed by the QI 28. Clinically significant abnormal laboratory results at screening as assessed by the QI 29. Participation in a clinical research trial within 30 days prior to randomization 30. Individuals who are cognitively impaired and/or who are unable to give informed consent 31. Any other condition which in the QI's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose a significant risk to the subject